Table 1 Patient characteristics (N=60)
Characteristics | No. of patients | % |
|---|---|---|
Donor status | ||
Related | 39 | 65 |
Unrelated | 21 | 35 |
Age at HSCT (years) | ||
–39 | 33 | 55 |
40– | 27 | 45 |
BCR–ABL isoform | ||
Minor | 42 | 70 |
Major | 18 | 30 |
Additional chromosome abnormality (4 subjects unknown) | ||
No | 10 | 17 |
Yes | 44 | 83 |
WBC at diagnosis ( × 10 9 /l) | ||
<30 | 34 | 57 |
⩾30 | 26 | 43 |
CD 20 positivity (9 subjects unknown) | ||
Negative | 28 | 47 |
Positive | 23 | 38 |
Stem-cell source | ||
Bone marrow | 35 | 58 |
Peripheral blood | 16 | 27 |
Cord blood | 9 | 15 |
Conditioning regimen | ||
Myeloablative | 54 | 90 |
CY + TBI | 27 | 45 |
CY + CA + TBI | 15 | 25 |
CY + VP + TBI | 1 | 2 |
CY + TESPA + TBI | 4 | 7 |
CY + BU | 3 | 5 |
Others | 4 | 7 |
Reduced intensity | 6 | 10 |
Flu + BU | 3 | 5 |
Flu + LPAM ± TBI | 3 | 5 |
Performance status at HSCT | ||
0 | 39 | 65 |
1–2 | 21 | 35 |
MRD status at HSCT (3 subjects unknown) | ||
PCR negative | 39 | 65 |
PCR positive | 18 | 30 |
GVHD prophylaxis | ||
Cyclosporine + sMTX | 31 | 52 |
Cyclosporine ± other | 4 | 7 |
Tacrolimus + sMTX | 23 | 38 |
Others | 2 | 3 |
